Pfizer reports a drug-related death in tofacitinib trial

04/21/2011 | Wall Street Journal, The

Pfizer confirmed that one of four deaths during a clinical study of tofacitinib, a drug candidate for rheumatoid arthritis, was related to the drug. The company said tofacitinib-related mortality across several trials "is within the range of rates reported for biologic therapies" for the condition. Pfizer aims to market tofacitinib as an alternative to infused or injected treatments, such as Abbott Laboratories' Humira.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL